Capecitabine and Oxaliplatin Adjuvant Study in Stomach Cancer
Status:
Completed
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
Primary:
- To demonstrate that capecitabine/oxaliplatin as adjuvant chemotherapy is superior to
observation alone in terms of 3 year disease-free survival (DFS) rate in
chemotherapy-naïve patients who underwent potentially curative resection for gastric
cancer.
Secondary:
- To compare the overall survival of surgery and capecitabine/ oxaliplatin as adjuvant
therapy versus surgery alone. To evaluate the safety profile of capecitabine/oxaliplatin
adjuvant therapy.